MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Sodium Salicylate

CAS No. : 54-21-7

MCE 站：Sodium Salicylate

产品活性：Sodium Salicylate (Salicylic acid sodium salt) 抑制 COX-2 活性，抑制作用与转录因子 (NF-κB) 激活无关。Sodium Salicylate 还是一种 S6K 的抑制剂. Sodium Salicylate 是一种 NF-κB 抑制剂，可降低炎症基因的表达，促进老化肌肉的修复。

研究领域：Immunology/Inflammation  |  NF-κB  |  MAPK/ERK Pathway  |  Autophagy  |  Apoptosis

作用靶点：COX  |  NF-κB  |  Ribosomal S6 Kinase (RSK)  |  Autophagy  |  Apoptosis

In Vitro: Sodium Salicylate is an effective inhibitor of COX-2 activity at concentrations far below those required to inhibit NF-κB (20 mg/mL) activation. Sodium Salicylate inhibits prostaglandin E₂ release when add together with interleukin 1β for 24 hr with an IC₅₀ value of 5 μg/mL, an effect that is independent of NF-κB activation or COX-2 transcription or translation. Sodium Salicylate acutely (30 min) also causes a concentration-dependent inhibition of COX-2 activity measured in the presence of 0, 1, or 10 μM exogenous arachidonic acid. In contrast, when exogenous arachidonic acid is increased to 30 μM, Sodium Salicylate is a very weak inhibitor of COX-2 activity with an IC₅₀ of >100 μg/mL. When added together with IL-1β for 24 hr, Sodium Salicylate causes a concentration-dependent inhibition of PGE₂ release with an apparent IC₅₀ value of approximately 5 μg/mL. The ability of Sodium Salicylate to directly inhibit COX-2 activity in A549 cells is tested after a 30-min exposure period, followed by the addition of different concentrations of exogenous arachidonic acid (1, 10, and 30 μM). Sodium Salicylate causes a concentration-dependent inhibition of COX-2 activity in the absence of added arachidonic acid or in the presence of 1 or 10 μM exogenous substrate with an apparent IC₅₀ value of approximately 5 μg/mL. However, when the same experiments are performed using 30 μM arachidonic acid, Sodium Salicylate is an ineffective inhibitor of COX-2 activity, with an apparent IC₅₀ value of more than 100 μg/mL, and achieves a maximal inhibition of less than 50%.

In Vivo: In C57Bl/6 DIO mice, Salicylate decreases both fasting and postprandial plasma glucose levels. Furthermore, there is a trend to reduce plasma triglyceride levels after Salicylate treatment in C57Bl/6 DIO mice (P=0.059). Salicylate significantly reduces 11β-HSD1 mRNA in omental adipose tissue in C57Bl/6 DIO mice, with a similar trend in mesenteric adipose (P=0.057). In mesenteric adipose of C57Bl/6 DIO mice, Salicylate also reduces 11β-HSD1 enzyme activity.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Apoptosis Compound Library  |  Immunology/Inflammation Compound Library  |  Kinase Inhibitor Library  |  MAPK Compound Library  |  NF-κB Signaling Compound Library  |  Stem Cell Signaling Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Autophagy Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Antioxidants Compound Library  |  Differentiation Inducing Compound Library  |  Reprogramming Compound Library  |  Diabetes Related Compound Library  |  Oxygen Sensing Compound Library  |  Anti-COVID-19 Compound Library  |  NMPA-Approved Drug Library  |  Pyroptosis Compound Library  |  Orally Active Compound Library  |  Glutamine Metabolism Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Anti-Breast Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Gut Microbial Metabolite Library  |  Anti-Blood Cancer Compound Library  |  MG-132  |  LY294002  |  Doxorubicin hydrochloride  |  Bafilomycin A1  |  Paclitaxel  |  Y-27632 dihydrochloride  |  Acetylcysteine  |  Angiotensin II human  |  SP600125  |  5-Fluorouracil  |  Staurosporine  |  Bortezomib  |  Tamoxifen  |  2-Deoxy-D-glucose  |  Gemcitabine  |  Verteporfin  |  Decitabine  |  Actinomycin D  |  Temozolomide  |  BAY 11-7082  |  Etoposide  |  Mitomycin C  |  CCCP  |  DAPT  |  Rotenone  |  Etomoxir  |  Stattic  |  Docetaxel  |  Fulvestrant

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。